A Phase 2 Trial of Primary Tumor Stereotactic Body Radiation Therapy Boost Before Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer

医学 肿瘤科 放射治疗 肺癌 内科学 放射科
作者
Terence M. Williams,Eric D. Miller,M.X. Welliver,Jeremy Brownstein,Gregory A. Otterson,Dwight H. Owen,Karl Haglund,Peter G. Shields,Erin M. Bertino,Carolyn J. Presley,Kai He,Jacob Naduparambil,Steve Walston,Xueliang Pan,Xiangyu Yang,Michael V. Knopp,Jean Koutou Essan,Joseph P. McElroy,Xiaokui Mo,Sohyun L. McElroy
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:120 (3): 681-694 被引量:4
标识
DOI:10.1016/j.ijrobp.2024.02.020
摘要

ABSTRACT

BACKGROUND

Primary tumor failure is common in patients treated with chemoradiation (CRT) for locally-advanced NSCLC (LA-NSCLC). Stereotactic body radiation therapy (SBRT) yields high rates of primary tumor control (PTC) in early-stage NSCLC. This trial tested an SBRT boost to the primary tumor prior to the start of CRT to improve PTC.

MATERIALS/METHODS

Patients with LA-NSCLC received an SBRT boost in 2 fractions (central location 12 Gy, peripheral location 16 Gy) to the primary tumor, followed by standard CRT (60 Gy in 30 fractions). The primary objective was PTC rate at 1-year with a hypothesis that the 1-year PTC rate is ≥90%. Secondary objectives included objective response rate (ORR), regional & distant control, disease-free survival (DFS), and overall survival (OS). Correlative studies included functional MRI (fMRI) and blood-based miRNA analysis.

RESULTS

The study enrolled 21 patients (10 male, 11 female), with median age 62 years (range 52-78). Median pre-treatment primary tumor size was 5.0 cm (range 1.0-8.3). The most common non-hematologic toxicities were pneumonitis, fatigue, esophagitis/dysphagia, dyspnea, and cough. Only 1 treatment-related grade 4 non-hematologic toxicity occurred (respiratory failure/radiation pneumonitis), and there were no grade 5 toxicities. ORR at 3 and 6 months was 72.7% and 80.0%, and PTC at 1 and 2 years was 100% and 92.3%, respectively. The 2-year regional and distant control were 81.6% and 70.3%, respectively. DFS and OS at 2 yrs were 46.1% and 50.3%, respectively. Median survival was 37.8 months. fMRI detected a mean relative decrease in BOLD signal of -87.1% (p=0.05), and miR.142.3p correlated with increased risk of grade≥3 pulmonary toxicity (p=0.01).

CONCLUSIONS

Dose escalation to the primary tumor utilizing upfront SBRT appears feasible and safe. PTC was high and other oncologic endpoints compared favorably to standard treatment. fMRI suggested changes in oxygenation with the first SBRT boost dose, and miR.142.3p correlated with pulmonary toxicity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
123发布了新的文献求助10
1秒前
1秒前
欣喜豌豆发布了新的文献求助10
1秒前
科研达人发布了新的文献求助10
1秒前
bxkrystal完成签到,获得积分10
2秒前
3秒前
汉堡包应助lina采纳,获得10
3秒前
4秒前
陈某发布了新的文献求助10
5秒前
5秒前
丘比特应助sheri1采纳,获得10
6秒前
6秒前
6秒前
6秒前
7秒前
万能图书馆应助二掌柜采纳,获得10
7秒前
阳光易真发布了新的文献求助30
8秒前
wei完成签到,获得积分10
9秒前
9秒前
rita_sun1969发布了新的文献求助30
9秒前
9秒前
10秒前
10秒前
123完成签到,获得积分20
11秒前
华仔应助hyc采纳,获得10
11秒前
11秒前
咕嘟发布了新的文献求助10
11秒前
兔年吉祥完成签到,获得积分10
12秒前
owlhealth完成签到,获得积分10
12秒前
Orange应助llll采纳,获得10
13秒前
13秒前
大椒发布了新的文献求助10
13秒前
俞晓发布了新的文献求助10
13秒前
13秒前
冷青完成签到,获得积分10
14秒前
PT177245完成签到,获得积分10
14秒前
年轻小之发布了新的文献求助10
15秒前
搜集达人应助布溜采纳,获得10
15秒前
witty发布了新的文献求助10
16秒前
小鹿呀发布了新的文献求助10
18秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988827
求助须知:如何正确求助?哪些是违规求助? 3531197
关于积分的说明 11252739
捐赠科研通 3269830
什么是DOI,文献DOI怎么找? 1804815
邀请新用户注册赠送积分活动 881915
科研通“疑难数据库(出版商)”最低求助积分说明 809028